Marie Kersten

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2000 2019

Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study

van Dongen, J. M., Persoon, S., Jongeneel, G., Bosmans, J. E., Kersten, M. J., Brug, J., Nollet, F., Chinapaw, M. J. M. & Buffart, L. M., 1 Jan 2019, In : Journal of Cancer Survivorship.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 2019, In : Haematologica. 104, 4, p. e151-e153

Research output: Contribution to journalComment/Letter to the editorAcademic

Open Access

Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data

Sweegers, M. G., Altenburg, T. M., Brug, J., May, A. M., van Vulpen, J. K., Aaronson, N. K., Arbane, G., Bohus, M., Courneya, K. S., Daley, A. J., Galvao, D. A., Garrod, R., Griffith, K. A., Van Harten, W. H., Hayes, S. C., Herrero-Román, F., Kersten, M. J., Lucia, A., McConnachie, A., van Mechelen, W. & 19 othersMutrie, N., Newton, R. U., Nollet, F., Potthoff, K., Schmidt, M. E., Schmitz, K. H., Schulz, K. H., Sonke, G., Steindorf, K., Stuiver, M. M., Taaffe, D. R., Thorsen, L., Twisk, J. W., Velthuis, M. J., Wenzel, J., Winters-Stone, K. M., Wiskemann, J., Chin A Paw, M. J. & Buffart, L. M., 4 Sep 2018, In : British journal of sports medicine.

Research output: Contribution to journalReview articleAcademicpeer-review

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K. & Kersten, M. J., 2018, In : Blood cancer journal. 8, 2, 16.

Research output: Contribution to journalComment/Letter to the editorAcademic